Mecobalamin

ApprovedCompleted

2 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Dementia With Vitamin B12 Deficiency

Conditions

Dementia With Vitamin B12 Deficiency

Trial Timeline

Mar 1, 2003 → —

NCT ID

NCT00165711

About Mecobalamin

Mecobalamin is a approved stage product being developed by Eisai for Dementia With Vitamin B12 Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00165711. Target conditions include Dementia With Vitamin B12 Deficiency.

What happened to similar drugs?

8 of 20 similar drugs in Dementia With Vitamin B12 Deficiency were approved

Approved (8) Terminated (1) Active (11)

✅E2020 + PlaceboEisaiApproved

✅donepezil hydrochloride (Aricept)EisaiApproved

✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved

✅Risperdal,reminylJohnson & JohnsonApproved

✅ENA713NovartisApproved

✅Rivastigmine Patch 9.5 cm2NovartisApproved

✅Memantine + PlaceboLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00165711	Approved	Completed	Mar 1, 2003	—	Dementia With Vitamin B12 Deficiency

Competing Products

20 competing products in Dementia With Vitamin B12 Deficiency

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 3	26
AL001 + Placebo + Open label - AL001	Alector	Phase 3	22
AL001	Alector	Phase 2	25
ATH-1017 + Placebo	LeonaBio	Phase 2	17
IGC AD1 + Placebo	IGC Pharma	Phase 1	19
E2020 + Placebo	Eisai	Approved	43
ARICEPT	Eisai	Phase 3	40
Rasagiline	Eisai	Phase 2	35
Donepezil Hydrochloride	Eisai	Pre-clinical	26
donepezil hcl	Eisai	Phase 3	40
Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo	Eisai	Phase 3	40
E2020 + E2020	Eisai	Phase 2	35
donepezil hydrochloride (Aricept)	Eisai	Approved	43
3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo	Eisai	Phase 2	35
E2020 + E2020	Eisai	Phase 3	40
Irsenontrine + Placebo	Eisai	Phase 2	35
E2020	Eisai	Phase 2	35
E2020 + Placebo	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Phase 3	40
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	43